A PHASE 1, FIXED-SEQUENCE, OPEN LABEL STUDY TO EVALUATE THE EFFECT OF PF-06651600 ON PHARMACOKINETICS OF SINGLE DOSE SUMATRIPTAN IN HEALTHY PARTICIPANTS
Latest Information Update: 07 Sep 2020
At a glance
- Drugs Ritlecitinib (Primary) ; Sumatriptan (Primary)
- Indications Alopecia areata; Crohn's disease; Rheumatoid arthritis; Ulcerative colitis; Vitiligo
- Focus Pharmacokinetics
- Sponsors Pfizer
- 01 Sep 2020 Status changed from recruiting to completed.
- 23 Jun 2020 Planned End Date changed from 13 Aug 2020 to 9 Aug 2020.
- 23 Jun 2020 Planned primary completion date changed from 13 Aug 2020 to 9 Aug 2020.